Sign up online today & collaborate
or click here to find out more
Shares in Tekmira have taken a downturn after it emerged that its experimental Ebola vaccine was unlikely to hit efficacy goals in a mid-stage trial.
The Vancouver, Canada-based group said it has stopped enrolment in the Phase II, Sierra Leone-based trial after a predefined statistical endpoint indicated that there was not likely to be an overall therapeutic benefit from its jab.
For more click here